Lead Program ZAC-3: The First Biologic Against Cholera

Cholera remains a significant cause of morbidity and mortality in low- and middle-income countries (LMICs), especially in regions suffering from civil unrest and infrastructure breakdown. Despite the success of oral cholera vaccines, there remains a dire need for an effective pre-exposure prophylactic (PrEP) for use in outbreak situations where disease spread outpaces vaccine implementation.

•   ZAC-3 is a novel prophylactic monoclonal antibody (“mAb”) against V. Cholerae targeting the O1 and O139 serotypes LPS.

•   We’ve engineered extended half-life for improved efficacy.

•   Our goal is a < $10 cost per-dose through concentrated fed-batch or continuous manufacturing at commercial scale.

•   We are developing a subcutaneous injection for ease of delivery.

•   Our formulation efforts are intended to mitigate the need for intensive cold-chain logistics.

•   Our efforts are aimed at deploying ZAC-3 to challenging environments including displaced persons settlements.

Collaborators: ServareGMP, Mapp Biopharmaceutical and Wadsworth Center, Division of Infectious Diseases, NY State Dept. of Health. Pre-clinical studies are projected for Q3/4, 2022.

This program creates a new pathway to deploy low-cost mAbs against infectious diseases where limited resources are a roadblock to use. We intend to deliver very low cost and free medicines to our target populations.